Stay updated on Nivolumab Combo in Early Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in Early Lung Cancer Clinical Trial page.

Latest updates to the Nivolumab Combo in Early Lung Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study record now shows Terminated due to slow accrual and lack of funding, and results have been posted. The summary also includes the Major Pathologic Response (mpCR) definition and related outcome measures.SummaryDifference3%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded Revision: v3.4.2. The prior government funding/status notice (Revision: v3.4.1) was removed.SummaryDifference0.4%

- Check31 days agoChange DetectedAdded a site-wide notice about potential delays due to a lapse in government funding and updated the page revision to v3.4.1; the previous revision v3.4.0 was removed.SummaryDifference0.4%

- Check38 days agoChange DetectedThe glossary is now shown by default and the QC status label has been updated to 'Last Update Submitted that Met QC Criteria' with a new version reference v3.4.0. The previous label 'Last Update Submitted that met QC Criteria', the 'No FEAR Act data' label, and the older version reference v3.3.4 were removed.SummaryDifference0.2%

- Check52 days agoChange DetectedRevision: v3.3.4 is now displayed, replacing v3.3.3; no study details or navigation elements appear to be changed.SummaryDifference0.1%

- Check74 days agoChange DetectedLocations updated to include Pennsylvania; HHS Vulnerability Disclosure removed; page revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Combo in Early Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Early Lung Cancer Clinical Trial page.